Real-World Endpoints in Stereotactic Body Radiation Therapy Trials for Oligoprogression: Beyond Progression-Free Survival and Overall Survival
Authors:
- 29 December 2025
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (1) , 36-39
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyThe Lancet, 2023
- Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumorsFuture Oncology, 2023
- Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trialESMO Open, 2021
- Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous LymphomaCancers, 2020
- Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendationThe Lancet Oncology, 2020
- The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?Clinical Oncology, 2019
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009